Welcome to our dedicated page for ORGANON & CO SEC filings (Ticker: OGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Organon & Co. (NYSE: OGN) provide detailed, regulatory-grade insight into the operations of a global healthcare company focused on Women’s Health, General Medicines and biosimilars. Through current reports on Form 8-K and related amendments, Organon discloses quarterly earnings information, leadership changes, governance matters and the status of internal controls over financial reporting.
Recent 8-K filings furnish earnings releases for quarters such as the period ended June 30, 2025 and September 30, 2025, along with investor presentations that discuss revenue by segment, non-GAAP measures like Adjusted EBITDA and Adjusted gross margin, and capital allocation decisions including dividends. These filings help readers understand how Organon’s women’s health, biosimilars and established brands portfolios contribute to overall performance.
Other 8-Ks and an 8-K/A detail material governance events, including the resignation of the Chief Executive Officer, the appointment of an Interim Chief Executive Officer and an Executive Chair, and compensation arrangements for these roles. Filings also summarize the Audit Committee investigation into wholesaler sales practices for Nexplanon, the determination that certain practices were improper, and the conclusion that previously issued financial statements do not require restatement, while management’s prior assessment of internal control effectiveness must be revised.
On this page, users can review Organon’s SEC disclosures alongside AI-powered summaries that clarify the significance of each document. Filings such as earnings 8-Ks, future annual reports on Form 10-K, quarterly reports on Form 10-Q and any proxy or insider transaction reports can be examined to track segment performance, internal control remediation, leadership structure and other regulatory matters. Real-time updates from EDGAR combined with AI explanations can help investors and researchers interpret complex language, identify key risk and governance themes, and follow Organon’s ongoing reporting obligations.
Organon & Co. interim executive Juliana Papa reported a large equity compensation grant and related vesting activity. On March 31, 2026, she received 125,208 restricted stock units (RSUs), each representing a contingent right to one share of Organon common stock. These RSUs will vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
On the same date, previously granted RSUs vested and were converted into common shares through exercises of 6,378 and 10,073 RSUs. To cover tax obligations, 2,185 and 3,451 common shares were withheld at a price of $5.70 per share. After these transactions, Papa directly holds 33,235.703 shares of common stock and 20,148 RSUs.
Organon & Co. Head of R&D & CMO Juan Camilo Arjona Ferreira reported equity compensation and related share movements. On March 31, 2026, he received a grant of 200,333 Restricted Stock Units (RSUs), each representing one share of Organon common stock, vesting in three equal installments on March 31, 2027, 2028, and 2029.
On the same date, he exercised 13,431 RSUs from a prior March 31, 2025 grant, receiving an equal number of common shares. Of these, 4,820 shares of common stock were withheld at $5.70 per share to cover tax obligations. Following these transactions, he directly holds 30,047.477 shares of common stock and 200,333 RSUs.
Organon & Co. executive Daniel Karp reported several equity compensation moves involving Restricted Stock Units (RSUs) and common stock. On March 31, 2026, he received a grant of 100,166 RSUs, each representing a contingent right to one share of Organon common stock. These RSUs vest in three equal installments on March 31, 2027, 2028, and 2029.
On the same date, previously granted RSUs from March 31, 2023 and March 31, 2025 partially vested, converting 11,338 and 6,715 RSUs, respectively, into common shares. To cover tax obligations, 3,554 and 2,105 common shares were withheld at a price of $5.70 per share. After these transactions, Karp directly held 69,547.923 shares of Organon common stock, alongside the new unvested RSU grant.
Organon & Co. Chief Information Officer Rachel A. Stahler reported compensation-related stock activity. She was granted 183,639 restricted stock units (RSUs) on March 31, 2026, each representing a contingent right to one share of Organon common stock, vesting in three equal installments on March 31, 2027, 2028, and 2029.
On the same date, previously granted RSUs from March 31, 2023 and March 31, 2025 vested and were exercised into common shares. A total of 6,463 shares of common stock were withheld at a price of $5.70 per share to cover tax obligations. After these transactions, Stahler directly holds 116,105.292 shares of Organon common stock.
Organon & Co. Chief Financial Officer Matthew M. Walsh reported a series of equity compensation transactions in Organon common stock. On March 31, 2026, he was granted 321,368 restricted stock units (RSUs) and a separate grant of 83,472 RSUs, each RSU representing a contingent right to one share of common stock. These RSUs will vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. On the same date, portions of earlier RSU awards granted in 2023 and 2025 vested and were exercised into common stock, while 4,127 and 7,380 shares were withheld at $5.70 per share to cover tax obligations. Following these transactions, Walsh directly holds 212,746 shares of Organon common stock.
Organon & Co. Chief Human Resources Officer Aaron Falcione reported equity compensation activity involving restricted stock units (RSUs) and common stock. On March 31, 2026, he received a grant of 166,944 RSUs, each representing a contingent right to one share of Organon common stock.
The new RSUs vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. On the same date, previously granted RSUs vested and were converted into 6,732 and 11,193 shares of common stock. To satisfy tax obligations, 2,306 and 3,834 shares were withheld at a price of $5.70 per share.
After these transactions, Falcione directly owned 101,431.071 shares of Organon common stock and held 166,944 RSUs subject to future vesting.
Organon & Co. general counsel Kirke Weaver reported compensation-related equity activity. On March 31, 2026, Weaver received a grant of 183,639 Restricted Stock Units (RSUs), each representing a contingent right to one share of Organon common stock. These RSUs vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
On the same date, previously granted RSUs vested and were exercised into 18,513 shares of common stock. To cover tax obligations, 5,275 shares were withheld at a price based on the March 30, 2026 closing market price of $5.70 per share. After these transactions, Weaver directly owned 92,639.163 shares of Organon common stock.
Organon & Co. executive Vittorio Nisita reported routine equity compensation activity. On March 31, 2026, Nisita received a grant of 125,208 Restricted Stock Units (RSUs), each representing a contingent right to one share of Organon common stock. These RSUs will vest in three equal installments on March 31, 2027, 2028, and 2029.
On the same date, portions of earlier RSU grants from 2023 and 2025 vested, converting into a total of 13,000 shares of common stock. To satisfy tax obligations, 4,453 shares were withheld at a reference price of $5.70 per share, leaving Nisita with 70,619.158 common shares held directly after these transactions.
Organon & Co. senior vice president and corporate controller Lynette Holzbaur reported equity compensation and related share activity. On March 31, 2026, she received grants of 75,125 and 41,736 Restricted Stock Units (RSUs), each RSU representing a contingent right to one share of Organon common stock. These RSUs will vest in three equal installments on March 31, 2027, 2028, and 2029.
The filing also shows vesting of earlier RSU awards from March 31, 2023 and March 31, 2025, with the remaining one‑third of those grants converting into common shares. As part of the vesting, 1,212 and 1,914 shares of common stock were withheld at $5.70 per share to satisfy tax obligations, a non‑market disposition. Following these transactions, Holzbaur holds 26,402.427 shares of Organon common stock directly. The activity reflects routine compensation grants, vesting, and tax withholding rather than open‑market buying or selling.
Organon & Co. interim CEO Joseph T. Morrissey Jr. reported compensation-related equity activity in Organon stock. On March 31, 2026, he received a grant of 333,889 Restricted Stock Units (RSUs), each representing one share of common stock, vesting in three equal installments on March 31, 2027, 2028, and 2029.
He also exercised previously granted RSUs into common stock and had shares withheld to cover tax obligations. In total, 24,584 RSUs were converted into common stock, with 7,005 shares withheld at $5.70 per share for taxes. Following these transactions, he directly holds 123,122.923 shares of Organon common stock and 333,889 RSUs subject to future vesting.